Uremia
Conditions
Interventions
Step1: LIPUS intervention group:Low intensity pulse ultrasound (LIPUS) intervenes at the anastomotic site, and if the ultrasound examination indicates the presence of a narrow site in the outflow trac
Step1: Simulated LIPUS control group:Using the same forearm wearable portable ultrasound as the LIPUS arteriovenous fistula intervention group, but not issuing low-intensity pulse ultrasound.
Step2: LIPUS intervention group:Low intensity pulse ultrasound (LIPUS) intervenes at the anastomotic site, and if the ultrasound examination indicates the presence of a narrow site in the outflow trac
Step2: Simulated LIPUS control group:Using the same forearm wearable portable ultrasound as the LIPUS arteriovenous fistula intervention group, but not issuing low-intensity pulse ultrasound.
Sponsors
The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.18 years old = Age = 75 years old, regardless of gender or ethnicity; 2. Dialysis or non-dialysis patients who have newly established autologous arteriovenous fistula in the wrist and have not yet used the fistula for hemodialysis treatment; 3. Before establishing an autologous arteriovenous fistula in the wrist, ultrasound examination was performed. The radial artery diameter at the intended surgical site was>1.5mm, and the head vein diameter was>2mm (using a tourniquet). The arterial and venous blood flow was unobstructed, and the distance between the vein and the skin was<6mm; 4. After introducing dialysis, the calcium ion concentration in the dialysate was maintained at 1.5mmol/L during the dialysis period, and low molecular weight heparin was used for anticoagulation. The dosage of low molecular weight heparin remained unchanged (± 1000U) during the study period; 5. Sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Poor healing of internal fistula surgical incision; 2. Active bacterial or viral infections; 3. Pregnant women; 4. The patient underwent kidney transplantation or was transferred to peritoneal dialysis during the study period; 5. Subject ALT, AST = 3 × upper limit of normal values; 6. Within 3 months, according to NYHA classification, heart function is classified as level III-IV; 7. Newly diagnosed unstable angina and cerebrovascular events within 3 months; 8. Blood pressure below 90/60mmHg or above 180/100mmHg in the past 2 weeks; 9. During the study period, patients did not follow medical advice and arbitrarily changed the types and dosages of other anticoagulants or anticoagulants (such as aspirin, clopidogrel, Agatroban, etc.); 10. Combine the use of glucocorticoids and immunosuppressants, such as tacrolimus, cyclosporine, MMF, azathioprine, leflunomide, Tripterygium wilfordii glycosides, etc; 11. Other researchers consider inappropriate situations, such as coexisting with malignant tumors, where the expected lifespan is less than 6 months; 12. I have participated in other clinical trials within 4 weeks prior to the start of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maturity rate of arteriovenous fistula; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in hemodynamic parameters (blood flow, minimum outflow venous diameter), primary patency rate, secondary patency rate.; | — |
Countries
China
Contacts
Public ContactXiangqing Kong
The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital
Outcome results
None listed